Alembic Pharmaceuticals today reported 7.17 per cent increase in net profit at Rs 70.66 crore for the third quarter ended December 31, 2014-15.
It had posted net profit of Rs 65.93 crore in the same quarter of the 2013-14 fiscal, Alembic Pharma said in a filing to the BSE.
Net sales during the period under review stood at Rs 514.9 crore as against Rs 486.74 crore in the year-ago quarter, the company said.
Branded formulations business in India posted sales of Rs 250 crore as against Rs 225.1 crore, up 11 per cent, while speciality and acute segments grew by 19 per cent and 3 per cent respectively, it added.
International generic formulation posted a growth of 3 per cent at Rs 133.3 crore as compared to Rs 129.6 crore a year-ago.
During the quarter, the company filed one abbreviated new drug application (ANDAs) and received approval for one. It also filed two drug master file (DMF) applications during the period.
Alembic Pharmaceuticals stock closed over 11 per cent down at Rs 429.55 apiece on the BSE.